One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Another year in the grip of COVID-19 with slow recovery
J. Ring
doi : 10.1111/jdv.17765
Volume 35, Issue 12 p. 2340-2341
Refining how we measure as we test: new insights using adalimumab in patients with hidradenitis suppurativa
R.S. Gibson,A.B. Kimball
doi : 10.1111/jdv.17741
Volume 35, Issue 12 p. 2342-2342
Pioneers in Dermatology and Venereology: an interview with Professor John R. Stanley
J.R. Stanley
doi : 10.1111/jdv.17739
Volume 35, Issue 12 p. 2343-2345
Skin conditions among 20th century politicians and world leaders
N. Kluger,A. Perciaccante,P. Charlier,P. Vabres
doi : 10.1111/jdv.17545
Volume 35, Issue 12 p. 2346-2348
Practical management of epidermolysis bullosa: consensus clinical position statement from the European Reference Network for Rare Skin Diseases
C. Has,M. El Hachem,H. Bu?ková,P. Fischer,M. Friedová,C. Greco,P. Nevoránková,C. Salavastru,J.E. Mellerio,G. Zambruno,C. Bodemer
doi : 10.1111/jdv.17629
Volume 35, Issue 12 p. 2349-2360
Inherited epidermolysis bullosa (EB) comprises rare disorders that manifest with fragility and blistering of the skin and mucous membranes, with variable clinical severity. Management of EB is challenging due to disease rarity and complexity, the wide range of extracutaneous manifestations and a profound impact on daily life for the patient and family members. Although reference centres providing multidisciplinary care for EB exist in each European country, it is common for healthcare professionals that are not specialized in this rare disorder to treat EB patients. Here, experts of the European Reference Network for Rare and Undiagnosed Skin Diseases (ERN-Skin, https://ern-skin.eu) propose practical recommendations for the diagnosis and management of the commonest clinical issues, skin blisters and wounds, oral manifestations, pain and itch.
The value of dermoscopy of the nail plate free edge and hyponychium
M. Iorizzo,M. Starace,A. Di Altobrando,A. Alessandrini,L. Veneziano,B.M. Piraccini
doi : 10.1111/jdv.17521
Volume 35, Issue 12 p. 2361-2366
The non-invasive examination of the nail unit using a dermoscope is known as onychoscopy. This technique has become increasingly appreciated to facilitate the clinical diagnosis of nail disorders, opening up a valuable second front with a potential to avoid invasive diagnostic procedures. During a nail consultation, the nail unit should always be examined with the aid of a dermatoscope in all its components. The aim of this paper was to provide practical information about onychoscopy of the nail plate free edge and hyponychium, two components of the nail unit difficult to evaluate at naked eye and often forgotten, but of paramount importance.
Network meta-analyses in psoriasis: overview and critical discussion
M. Augustin,M. Valencia López,K. Reich
doi : 10.1111/jdv.17650
Volume 35, Issue 12 p. 2367-2376
Network meta-analyses (NMAs) increasingly assist in treatment decisions in disease areas such as psoriasis, where data from multiple clinical trials (CTs) on a growing number of different drugs become available. This study aimed to characterize NMAs published in psoriasis. A systematic literature search in PubMed was conducted using a structured search protocol based on the PRISMA criteria. Twenty-seven NMAs were identified, including an average of 43 CTs per NMA. Only eight of 27 NMAs (29.6%) were documented in the PROSPERO registry and only 17 (63%) reported following the PRISMA criteria. The mean number of patients per NMA was 19?624 (range: 6113–51?749). Across all NMAs, the drugs most frequently included were ustekinumab (n?=?27 NMAs), followed by adalimumab (n?=?25), infliximab and etanercept (n?=?24 each). In all n?=?27 NMAs, placebo comparisons and in n?=?25, comparisons with active controls were used for bridging. Effect estimates were performed in all cases, SUCRA in 14. Most frequently used outcomes were Psoriasis Area and Severity Index (PASI) 75 (n?=?25) and PASI 90 (n?=?24), and Dermatology Life Quality Index (n?=?10). NMAs mostly measured induction efficacy (weeks 10–16, n?=?25) but rarely long-term outcomes (weeks 48–56, n?=?4). Sensitivity analyses were performed in n?=?17 (63%) of the studies. Main results varied considerably between studies and depended on the year of publication and thus the number of available drugs and studies. However, the concordance between NMA efficacy rankings based on PASI 75 was high. Although a large number of NMAs have been published on psoriasis showing highly comparable results on efficacy, no sufficient information on the quality criteria was reported, and PROSPERO registry criteria were not followed. This argues in favour of greater standardization of NMA methodology and reporting.
Quality of life in patients with Mycosis Fungoides and Sézary Syndrome: a systematic review of the literature
R. Ottevanger,S. van Beugen,A.W.M. Evers,R. Willemze,M.H. Vermeer,K.D. Quint
doi : 10.1111/jdv.17570
Volume 35, Issue 12 p. 2377-2387
Cutaneous T-cell Lymphoma’s (CTCL) are a rare, heterogeneous group of T-cell lymphomas that primarily manifest in the skin. Mycosis fungoides (MF) and Sézary syndrome (SS) are considered the classic types of CTCL. The diverse manifestation of CTCL results in a wide range of symptoms with a possible mild to severe impact on Quality of Life (QoL) depending on the disease stage. Previous studies on QoL in CTCL patients report diverse patient populations and use many different QoL instruments. In the current literature, a clear overview on the influence of the different stages of disease (early MF, late-stage MF/SS or total group) on the QoL is lacking. Therefore, a systematic search of the literature was conducted using the PubMed, Embase, PsycINFO and Web of Science databases. Studies were included if they described QoL in patients with MF and SS retrieved by standardized instruments or qualitative interviews. In total, 24 studies were included using 18 different questionnaires to report on dermatology-specific, cancer-specific and generic QoL. The effect on QoL was found to be greater in patients with late-stage disease as compared to early stage disease, with significant impairments on functional, emotional and physical domains. Nonetheless, even in patients with limited disease, QoL was mildly to moderately affected. Overall, pruritus was the most frequent reported and most bothersome symptom. Significant influence of the disease on daily life activities were found, not only in patients but also on caregivers and family. This broad, structured overview on QoL in MF and SS patients underlines the influence of disease stage on QoL, and therefore, recommends future studies to distinguish between disease stages when reporting results. Furthermore, this overview can inform clinicians in clinical practice by creating awareness of QoL deficits according to disease stage.
Line-field confocal optical coherence tomography for the in?vivo real-time diagnosis of different stages of keratinocyte skin cancer: a preliminary study
C. Ruini,S. Schuh,C. Gust,B. Kendziora,L. Frommherz,L.E. French,D. Hartmann,J. Welzel,E.C. Sattler
doi : 10.1111/jdv.17603
Volume 35, Issue 12 p. 2388-2397
The treatment of keratinocyte cancers (KC) strictly depends on their differentiation and invasiveness. Non-invasive diagnostic techniques can support the diagnosis in real time, avoiding unnecessary biopsies. This study aimed to preliminarily define main imaging criteria and histological correlations of actinic keratosis (AK), Bowen’s disease (BD) and squamous cell carcinoma (SCC) using the novel device line-field confocal optical coherence tomography (LC-OCT).
Three-year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial
R. B. Warren,M. Lebwohl,H. Sofen,V. Piguet,M. Augustin,F. Brock,C.?Arendt,F. Fierens,A. Blauvelt
doi : 10.1111/jdv.17486
Volume 35, Issue 12 p. 2398-2408
Certolizumab pegol (CZP) is an Fc-free, PEGylated anti-tumor necrosis factor biologic.
Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis
K. Reich,U. Mrowietz,A. Menter,C.E.M. Griffiths,J. Bagel,B. Strober,N. Nunez Gomez,R. Shi,B. Guerette,M. Lebwohl
doi : 10.1111/jdv.17520
Volume 35, Issue 12 p. 2409-2414
Treating to absolute treatment targets rather than relative measures such as Psoriasis Area and Severity Index (PASI)-75 is emerging as an important clinical concept included in psoriasis guidelines and clinical practice. Achieving treatment targets is associated with achievement of long-term outcomes.
Specific features of amoxicillin-associated Drug Reaction with Eosinophilia and Systemic Symptoms syndrome: a nationwide study
B. Largeau,M.-S. Agier,F. Beau-Salinas,A. Pariente,A. Maruani,T. Vial,A.-P. Jonville-Béra
doi : 10.1111/jdv.17631
Volume 35, Issue 12 p. 2415-2420
Growing evidence indicates that amoxicillin induces herpesvirus replication in?vitro. As these play a central pathophysiological role in Drug Reaction with Eosinophilia and Systemic Symptoms syndrome (DRESS), amoxicillin could present with specific DRESS features.
Variability of disease activity in patients with hereditary angioedema type 1/2: longitudinal data from the Icatibant Outcome Survey
M. Maurer,T. Caballero,W. Aberer,A. Zanichelli,L. Bouillet,A. Bygum,A.S. Grumach,J. Botha,I. Andresen,H.J. Longhurst,for the IOS Study Group
doi : 10.1111/jdv.17654
Volume 35, Issue 12 p. 2421-2430
Hereditary angioedema due to C1 inhibitor deficiency (HAE-1/2) is a chronic and debilitating disease. The unpredictable clinical course represents a significant patient burden.
Real-world effectiveness of adalimumab in patients with moderate-to-severe hidradenitis suppurativa: the 1-year SOLACE study
W. Gulliver,A. Alavi,M.C. Wiseman,M.J. Gooderham,J. Rao,M.S. Alam,K.A. Papp,O. Desjardins,C. Jean
doi : 10.1111/jdv.17598
Volume 35, Issue 12 p. 2431-2439
Long-term, real-word data are needed to help manage patients with hidradenitis suppurativa (HS) through this recurrent, painful and debilitating disease.
Clinicopathological characteristics and treatment outcomes of fibrosing alopecia in a pattern distribution: A?retrospective cohort study
R. Jerjen,J. Pinczewski,R. Sinclair,B. Bhoyrul
doi : 10.1111/jdv.17604
Volume 35, Issue 12 p. 2440-2447
Fibrosing alopecia in a pattern distribution (FAPD) is a primary cicatricial alopecia considered a subtype of lichen planopilaris (LPP).
Photodiagnostic services in the UK and Republic of Ireland: a British Photodermatology Group Workshop Report
S.H. Ibbotson,D. Allan,R.S. Dawe,E. Eadie,P.M. Farr,H. Fassihi,F. Fedele,J. Ferguson,A. Fityan,P. Freeman,L. Fullerton,V. Goulden,S. Haque,T.C. Ling,A. Mackay,K. McKenna,N. Ralph,L.E. Rhodes,R. Sarkany,D. Turner,S. Ungureanu,S. Weatherhead
doi : 10.1111/jdv.17632
Volume 35, Issue 12 p. 2448-2455
Photodiagnostic investigations are essential for the accurate diagnosis of abnormal cutaneous photosensitivity and provide important information for the management of patients with photodermatoses (cutaneous photosensitivity disorders). Although photodiagnosis has been undertaken since the early 1970s, specialist services in the United Kingdom (UK) and Republic of Ireland are limited and there is no formal guidance on diagnostic approach. Indeed, there is a limited literature in this area of methodology and diagnostic practice.
Clinicopathological features of cutaneous reactions after mRNA-based COVID-19 vaccines
M. Tihy,S. Menzinger,R. André,E. Laffitte,L. Toutous-Trellu,G. Kaya
doi : 10.1111/jdv.17633
Volume 35, Issue 12 p. 2456-2461
Cutaneous reactions, mostly on injection site after mRNA-based COVID-19 vaccines, have been reported but not with detailed histopathological characterization.
Corrigendum: Correlation between electrical impedance spectroscopy and the clinical and dermoscopic grading of actinic keratoses
B.M. Berger,G.R. Giuffrida,Z.I. Zalaudek,E.E. Eber,H.R. Hofmann-Wellenhof
doi : 10.1111/jdv.17624
Volume 35, Issue 12 p. 2462-2462
Corrigendum: an integrated approach is recommended in bullous pemphigoid
Françoise Poot
doi : 10.1111/jdv.17717
Volume 35, Issue 12 p. 2463-2463
Prevalence and characteristics of dermatological manifestations in COVID-19 positive dermatologists: Report from a web-based survey in India
D. Jakhar,A. Das,S. Kaul,I. Kaur,B. Madke,A. Dalal
doi : 10.1111/jdv.17532
Volume 35, Issue 12 p. e832-e833
Pityriasis rubra pilaris after Vaxzevria® COVID-19 vaccine
I. Lladó,B. Butrón,R. Sampedro-Ruiz,J. Fraga,D. de Argila
doi : 10.1111/jdv.17542
Volume 35, Issue 12 p. e833-e835
The impact of the COVID-19 pandemic on diagnostic delay of skin cancer: a call to restart screening activities
C. Dessinioti,C. Garbe,A.J. Stratigos
doi : 10.1111/jdv.17552
Volume 35, Issue 12 p. e836-e837
Cutaneous manifestations of patients hospitalized with coronavirus disease 2019 (COVID-19)
P. Ramezani Darmian,Z. Memarzadeh,R. Aryan,Y. Nahidi,Z. Mehri,A. Taghipour,N. Samimi,M. Amini,P. Layegh
doi : 10.1111/jdv.17557
Volume 35, Issue 12 p. e837-e839
Retiform purpura and extensive skin necrosis as the single manifestation of SARS-CoV-2 infection
M. Brito Caldeira,M. Pestana,A.L. João,C. Fernandes,A. João,N. Cunha
doi : 10.1111/jdv.17562
Volume 35, Issue 12 p. e839-e841
Cutaneous reactions to inactivated SARS-CoV-2 vaccine and ChAdOx1-S (recombinant) vaccine against SARS-CoV-2: a case series from the Philippines
J.N. Yu,C.B. Angeles,H.G. Lim,C. Chavez,C. Roxas-Rosete
doi : 10.1111/jdv.17575
Volume 35, Issue 12 p. e841-e845
Herpes zoster after ChAdOx1 nCoV-19 vaccine: a case series
M. Vastarella,V. Picone,F. Martora,G. Fabbrocini
doi : 10.1111/jdv.17576
Volume 35, Issue 12 p. e845-e846
Herpes zoster after inactivated SARS-CoV-2 vaccine in two healthy young adults
A.K. Özdemir,S. Kayhan,S.K. Çakmak
doi : 10.1111/jdv.17577
Volume 35, Issue 12 p. e846-e847
Rare cutaneous adverse effects of COVID-19 vaccines: a case series and review of the literature
E. Annabi,N. Dupin,P. Sohier,B. Garel,N. Franck,S. Aractingi,S. Guégan,B. Oulès
doi : 10.1111/jdv.17578
Volume 35, Issue 12 p. e847-e850
Late-onset pustular skin eruption in a healthy neonate born from COVID-positive mother: a coincidence or a new skin sign of the infection?
V. Piccolo,C. Mazzatenta,T. Russo,F. Morandi,A. Bassi,G. Argenziano,E. Valerio,R. Grimalt,M. Cutrone
doi : 10.1111/jdv.17579
Volume 35, Issue 12 p. e850-e852
Characteristics of facial skin problems and microbiome variation during wearing masks for fighting against COVID-19
C. Huang,Q. Sun,D. Jiang,X. Zhang,C. Chen,D. Yan,X. Liu,Y. Zhou,C. Ding,L. Lan,J. Wu,L. Li,A. Li,X. Liu,S. Yang
doi : 10.1111/jdv.17580
Volume 35, Issue 12 p. e853-e855
Three cases of vesiculobullous non-IgE-mediated cutaneous reactions to tozinameran (Pfizer-BioNTech COVID-19 vaccine)
L. Juay,N.S. Chandran
doi : 10.1111/jdv.17581
Volume 35, Issue 12 p. e855-e857
Psoriasis exacerbation after COVID-19 vaccination: a report of 14 cases from a single centre
E. Sotiriou,A. Tsentemeidou,K. Bakirtzi,A. Lallas,D. Ioannides,E. Vakirlis
doi : 10.1111/jdv.17582
Volume 35, Issue 12 p. e857-e859
Erythema gyratum repens after COVID-19
R. Castro Silva,G. Castro Silva,M.C. Castro Silva,O. Lupi
doi : 10.1111/jdv.17583
Volume 35, Issue 12 p. e859-e861
Cutaneous reactions following CoronaVac COVID-19 vaccination: a case series of six healthcare workers from a single centre
E. Akda?,B. Ö?üt,Ö. Erdem,M.O. Özta?,N. ?lter
doi : 10.1111/jdv.17592
Volume 35, Issue 12 p. e861-e864
A Bullous Eruption following the Pfizer-BioNTech COVID-19 vaccination
A. D’Cruz,H. Parker,M. Saha
doi : 10.1111/jdv.17606
Volume 35, Issue 12 p. e864-e865
SARS-CoV-2 in the sweat of COVID-19-positive patients: a possible route of transmission?
S. Recalcati,S. Tonolo,E. Meroni,F. Fantini
doi : 10.1111/jdv.17607
Volume 35, Issue 12 p. e865-e866
‘COVID vaccine arm’ may present after both mRNA vaccines vaccination
S. Gregoriou,I. A. Kleidona,A. Tsimpidakis,E. Nicolaidou,A. Stratigos,D. Rigopoulos
doi : 10.1111/jdv.17614
Volume 35, Issue 12 p. e867-e868
Two cases of papulo-pustular rosacea-like eruptions following COVID-19 vaccinations
G. Ciccarese,F. Drago,A. Rebora,A. Parodi
doi : 10.1111/jdv.17615
Volume 35, Issue 12 p. e868-e870
Scabies in monasteries in Phnom Penh, Cambodia
T. So,S. Un,K.D. Lestari,L.C. Fuller,I. Elyazar,C. Bendick,M.L. Grijsen
doi : 10.1111/jdv.17458
Volume 35, Issue 12 p. e871-e873
Gonorrhoea proctitis in men who have sex with men: The importance of performing culture specimens for antimicrobial resistance surveillance
D. Richardson,D. Trotman,J. Devlin,Z. Buss,R. Fortescue-Talwar,C. Fitzpatrick,D. Williams
doi : 10.1111/jdv.17503
Volume 35, Issue 12 p. e873-e875
To assess the relationship between distance travelled to dermatology clinic and Breslow thickness of melanoma at diagnosis
S.B. Bowe,C.G. Gallagher,M.O.C. O'Connell,L.P. Paul
doi : 10.1111/jdv.17515
Volume 35, Issue 12 p. e875-e876
Quincke, quincke-like and pseudo-quincke signs: nosology of cutaneous phenomena
S.H. Yale,H. Tekiner,E.S. Yale
doi : 10.1111/jdv.17516
Volume 35, Issue 12 p. e876-e877
Do AI models recognise rare, aggressive skin cancers? An assessment of a direct-to-consumer application in the diagnosis of Merkel cell carcinoma and amelanotic melanoma
L. Steele,D. Velazquez-Pimentel,B.R. Thomas
doi : 10.1111/jdv.17517
Volume 35, Issue 12 p. e877-e879
Treatment-specific evaluation of the modified Glasgow-Prognostic-Score in patients with advanced cutaneous melanoma
N. Pflug,M. Vitus,J. Knuever,S. Hamacher,C. Mauch,M. Schlaak,S. Theurich
doi : 10.1111/jdv.17533
Volume 35, Issue 12 p. e879-e883
Merkel cell carcinoma is still an unexpected diagnosis
H. Svensson,J. Paoli
doi : 10.1111/jdv.17534
Volume 35, Issue 12 p. e883-e884
Assessing the responsiveness of sonographic biomarkers to Brodalumab therapy in Hidradenitis Suppurativa
J.W. Frew,D. Grand,K. Navrazhina,S. Garcet,J.G. Krueger
doi : 10.1111/jdv.17536
Volume 35, Issue 12 p. e884-e887
Comment on: folliculitis decalvans and lichen planopilaris phenotypic spectrum: a case report of two paediatric cases
R.M. Trüeb
doi : 10.1111/jdv.17537
Volume 35, Issue 12 p. e888-e889
Scabies is becoming less sensitive to permethrin therapy
R. Balestri,M. Magnano,S.D. Infusino,L. Rizzoli,C.R. Girardelli,G. Rech
doi : 10.1111/jdv.17538
Volume 35, Issue 12 p. e889-e891
Cutaneous ulceration as primary presentation of TEMPI syndrome
J. Strobl,C. Sinz,P.M. Heil,G. Stary,W. Weninger
doi : 10.1111/jdv.17539
Volume 35, Issue 12 p. e891-e894
Acute generalized exanthematous pustulosis overlapping with toxic epidermal necrolysis successfully treated with etanercept
Z. Ridha,J. Guirguis,L. Ouchene,M. Chergui,I.V. Litvinov,E. Netchiporouk
doi : 10.1111/jdv.17540
Volume 35, Issue 12 p. e894-e896
Dupilumab in atopic dermatitis: predictors of treatment outcome and time to response
E. Nettis,S. M. Ferrucci,G. Pellacani,E. Di Leo,G. Argenziano,C. Foti,F. Rongioletti,C. Patruno,M. Ortoncelli,L. Macchia,S. Tavecchio,L. Bonzano,D. Di Bona,G. Calabrese,G. Fabbrocini,STUDY GROUP
doi : 10.1111/jdv.17541
Volume 35, Issue 12 p. e896-e898
A Genome-wide association study identified HLA-C associated with the effectiveness of methotrexate for psoriasis treatment
Y. Zhang,X. Ding,Z. Meng,M. Chen,X. Zheng,M. Cai,J. Wu,Y. Chang,Q. Zhang,L. Jin,D. Qian,X. Li,M. Wu,K. Yan,Y. Lu,X. Zhang
doi : 10.1111/jdv.17544
Volume 35, Issue 12 p. e898-e900
Line-field confocal optical coherence tomography of actinic keratosis: a case series
C. Lenoir,E. Cinotti,L. Tognetti,C. Orte Cano,G. Diet,M. Miyamoto,L. Rocq,A.-L. Trépant,J. Perez-Anker,S. Puig,J. Malvehy,P. Rubegni,J.-L. Perrot,V. del Marmol,M. Suppa
doi : 10.1111/jdv.17548
Volume 35, Issue 12 p. e900-e902
Trends of readmissions of atopic dermatitis patients in the United States: a 9-year longitudinal analysis of the Nationwide readmission database
E. Edigin,Z. El-Amir,F. Wani,A. Kichloo,P.O Eseaton
doi : 10.1111/jdv.17556
Volume 35, Issue 12 p. e903-e904
Miliarial type perifollicular B-cell pseudolymphoma: an easily overlooked rare subtype of pseudolymphoma cutis manifesting as a centrofacial acneiform eruption
P. Jauker,J. Tittes,A. Tanew
doi : 10.1111/jdv.17559
Volume 35, Issue 12 p. e905-e906
The challenge of palmoplantar pustulosis therapy: Are Interleukin-23 inhibitors an option?
S. Poortinga,G. Balakirski,C. Kromer,R. Mössner,M.P. Schön,T. Bieber,D. Wilsmann-Theis
doi : 10.1111/jdv.17560
Volume 35, Issue 12 p. e907-e911
Efficacy of ixekizumab on nail psoriasis in paediatric patients with moderate-to-severe psoriasis: a post hoc analysis from IXORA-PEDS
M.M.B. Seyger,A. Reich,C. El Baou,C. Schuster,E. Riedl,A.S. Paller
doi : 10.1111/jdv.17564
Volume 35, Issue 12 p. e911-e913
16S metagenomic assessment of the skin microbiota dynamic and possible association with the risk of infection in patients with epidermal necrolysis
J. Lavaud,S. Hüssler,G. Gricourt,N. de Prost,C. Rodriguez,S. Ingen-Housz-Oro,O. Chosidow,C. Bernigaud,P.L. Woerther
doi : 10.1111/jdv.17584
Volume 35, Issue 12 p. e914-e917
Apremilast in multibacillary leprosy patients with chronic and recurrent erythema nodosum leprosum: a prospective single-centre pilot study
T. Narang,R. Ashraf,A. Kaushik,S. Dogra
doi : 10.1111/jdv.17585
Volume 35, Issue 12 p. e917-e919
Air pollution and meteorological factors are associated with dermographism: a population-based study in college students
X. Gu,Y. Xiao,S. Li,J. Su,J. Li,S. Shan,X. Wang,B. Wu,J. Tao,X. Kang,B. Zou,X. Chen,M. Shen
doi : 10.1111/jdv.17586
Volume 35, Issue 12 p. e920-e921
Effective clinical study recruitment of patients with atopic dermatitis through social media
Z. Ali,K.M. Joergensen,C. Vestergaard,A.D. Andersen,M. Alexaki,A.L. Eiken,I. Manole,S.F. Thomsen,M. Deleuran,J.R. Zibert
doi : 10.1111/jdv.17587
Volume 35, Issue 12 p. e922-e923
Clinical determinants of complete response to vismodegib in locally advanced basal cell carcinoma: a multicentre experience
M.C. Fargnoli,C. Pellegrini,A. Piccerillo,G. Spallone,T. Rocco,A. Ventura,S. Necozione,L. Bianchi,K. Peris,A. Cortellini
doi : 10.1111/jdv.17588
Volume 35, Issue 12 p. e923-e926
The characteristics of men who have sex with men who present as sexual contacts of gonorrhoea from a clinic-based population
D. Richardson,K. Samarasekara,M. Ringshall,K. Parashar,K. Nichols,J. Devlin,Z. Buss,A. Pickering,C. Fitzpatrick,D. Williams
doi : 10.1111/jdv.17589
Volume 35, Issue 12 p. e926-e928
National trends of psoriasis hospitalizations: a 2-decade longitudinal United States population based study
E. Edigin,M.M. Rivera Pavon,P.O. Eseaton,A. Manadan
doi : 10.1111/jdv.17590
Volume 35, Issue 12 p. e928-e930
Reply to: low response of granulomatous cheilitis to currently established treatments
N.S. Ali,V.N. Sahni,B.C. Ma,D.R. Sahni,C.M. Hull,D.L. Powell,A.M. Secrest
doi : 10.1111/jdv.17591
Volume 35, Issue 12 p. e930-e931
Patient-reported outcomes with calcipotriol/betamethasone aerosol foam in patients with plaque psoriasis in Greece. Results from the CELSUS study
D. Rigopoulos,E. Lazaridou,E. Papadavid,S. Georgiou,V. Chasapi,K. Sfaelos,G. Cheliotis,D. Ioannides
doi : 10.1111/jdv.17593
Volume 35, Issue 12 p. e931-e934
Line-field confocal optical coherence tomography in molluscum contagiosum: a case series
A.E. Verzì,G. Micali,F. Lacarrubba
doi : 10.1111/jdv.17594
Volume 35, Issue 12 p. e934-e936
Evaluating the potential cost savings from inpatient dermatology consultations
P. Puri,M. Wiggins,M. Yousif,B.D. Pollock,L.P. Fox,M. Rosenbach,M.R. Pittelkow,A.R. Mangold
doi : 10.1111/jdv.17595
Volume 35, Issue 12 p. e936-e938
Efficacy assessment of a TCA/H2O2 compositum for skin ageing treatment by confocal laser microscopy and optical coherence tomography
F. Peccerillo,G. Odorici,S. Ciardo,M. Greco,S. Guida,F. Farnetani,G. Pellacani
doi : 10.1111/jdv.17596
Volume 35, Issue 12 p. e938-e942
